Specific gastric cancer population key to positive final NICE guidance on Roche's Herceptin
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has today published final guidance recommending Roche's anticancer Herceptin (trastuzumab) for some patients with metastatic gastric cancer. Defining a specific patient subgroup – patients who express high levels of HER2 – proved the key to winning a positive recommendation.